News coverage about Lannett Co (NYSE:LCI) has trended somewhat positive recently, according to Accern. The research group ranks the sentiment of press coverage by reviewing more than 20 million blog and news sources in real time. Accern ranks coverage of publicly-traded companies on a scale of -1 to 1, with scores closest to one being the most favorable. Lannett Co earned a daily sentiment score of 0.19 on Accern’s scale. Accern also gave media headlines about the company an impact score of 46.3366902262685 out of 100, meaning that recent press coverage is somewhat unlikely to have an impact on the company’s share price in the next few days.

These are some of the news stories that may have effected Accern Sentiment’s scoring:

A number of brokerages have recently weighed in on LCI. Oppenheimer Holdings, Inc. reiterated a “hold” rating on shares of Lannett Co in a report on Tuesday, May 2nd. Roth Capital set a $27.00 price target on Lannett Co and gave the company a “buy” rating in a report on Tuesday, May 2nd. Robert W. Baird reiterated an “outperform” rating and issued a $18.00 price target on shares of Lannett Co in a report on Wednesday, May 3rd. BMO Capital Markets began coverage on Lannett Co in a report on Monday, May 1st. They issued a “market perform” rating and a $29.00 price target for the company. Finally, Zacks Investment Research upgraded Lannett Co from a “hold” rating to a “buy” rating and set a $27.00 price target for the company in a report on Saturday, April 22nd. One investment analyst has rated the stock with a sell rating, five have assigned a hold rating and four have assigned a buy rating to the company’s stock. The stock currently has a consensus rating of “Hold” and a consensus price target of $27.50.

Lannett Co (NYSE LCI) traded up 2.40% on Monday, reaching $17.10. The company had a trading volume of 574,649 shares. The company has a 50-day moving average of $20.49 and a 200 day moving average of $21.48. Lannett Co has a one year low of $16.38 and a one year high of $39.99. The stock’s market cap is $636.63 million.

COPYRIGHT VIOLATION NOTICE: “Lannett Co (NYSE:LCI) Getting Somewhat Positive Media Coverage, Analysis Shows” was originally published by Daily Political and is owned by of Daily Political. If you are accessing this piece of content on another publication, it was stolen and reposted in violation of US & international trademark and copyright laws. The original version of this piece of content can be viewed at

About Lannett Co

Lannett Company, Inc develops, manufactures, markets and distributes generic versions of brand pharmaceutical products. The Company manufactures and/or distributes prescription products with the exception of a small portfolio of over-the-counter products manufactured by its subsidiary, Silarx Pharmaceuticals, Inc As of June 30, 2016, the Company’s products included Acetazolamide Tablets; Butalbital, Acetaminophen and Caffeine Tablets; Butalbital, Aspirin and Caffeine Capsules; C-Topical Solution; Digoxin Tablets; Glycolax Rx; Isosorbide Mononitrate CR; Levothyroxine Sodium Tablets; Methylphenidate HCL CD; Methylphenidate ER; Nifedipine CR; Omeprazole DR; Oxbutynin ER; Pantoprazole DR; Pilocarpine HCl Tablets; Triamterene w/Hydrochlorothiazide Capsules, and Ursodiol Capsules.

Insider Buying and Selling by Quarter for Lannett Co (NYSE:LCI)

Receive News & Ratings for Lannett Co Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Lannett Co Inc and related companies with's FREE daily email newsletter.